NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$4.02
+0.07 (+1.77 %)
(As of 09/23/2021 10:39 AM ET)
Add
Compare
Today's Range
$3.97
$4.03
50-Day Range
$1.93
$2.63
52-Week Range
$1.20
$6.57
Volume1,361 shs
Average Volume879,432 shs
Market Capitalization$368.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
30 days | 90 days | 365 days | Advanced Chart
Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.


OncoCyte logo

About OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.12 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view top-rated stocks.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) released its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.02. The biotechnology company had revenue of $2.03 million for the quarter, compared to analyst estimates of $1.65 million. OncoCyte had a negative net margin of 652.99% and a negative trailing twelve-month return on equity of 36.24%.
View OncoCyte's earnings history
.

How has OncoCyte's stock been impacted by COVID-19?

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OCX shares have increased by 87.9% and is now trading at $4.02.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OCX?

5 brokers have issued 12 month price objectives for OncoCyte's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate OncoCyte's stock price to reach $6.60 in the next year. This suggests a possible upside of 64.2% from the stock's current price.
View analysts' price targets for OncoCyte
or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Ronald Asbury Andrews, President, Chief Executive Officer & Director
  • Mitchell Stuart Levine, Chief Financial Officer
  • Douglas T. Ross, Chief Science Officer
  • Yu Li, Chief Accounting Officer, VP & Controller
  • Padma Sundar, Chief Commercial Officer

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.17%), Vanguard Group Inc. (4.27%), Nuveen Asset Management LLC (1.60%), Schonfeld Strategic Advisors LLC (1.52%), Defender Capital LLC. (1.47%) and State Street Corp (1.38%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Broadwood Partners, LP, Mitchell S Levine and Ronald Asbury Andrews.
View institutional ownership trends for OncoCyte
.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schonfeld Strategic Advisors LLC, Marshall Wace LLP, Marshall Wace LLP, Bridgeway Capital Management LLC, AWM Investment Company Inc., JPMorgan Chase & Co., and Millennium Management LLC.
View insider buying and selling activity for OncoCyte
or view top insider-selling stocks.

Which major investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC., Nuveen Asset Management LLC, Maven Securities LTD, Goldman Sachs Group Inc., Cinctive Capital Management LP, State Street Corp, Vanguard Group Inc., and Dimensional Fund Advisors LP. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Broadwood Partners, LP, Mitchell S Levine, and Ronald Asbury Andrews.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $4.02.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $368.16 million and generates $1.22 million in revenue each year. The biotechnology company earns $-29,930,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 51 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

Where are OncoCyte's headquarters?

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (949) 409-7600 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.